Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04434040 |
Recruitment Status :
Active, not recruiting
First Posted : June 16, 2020
Last Update Posted : January 23, 2024
|
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Genentech, Inc.
Stand Up To Cancer
Information provided by (Responsible Party):
Elizabeth A Mittendorf, MD, PhD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | December 30, 2025 |
Estimated Study Completion Date : | December 30, 2027 |